过去不必是序幕:针对下一次埃博拉病毒感染暴发的检测与最有前景医学对策定位的建议
本文回顾2013—2016年西非埃博拉病毒病暴发的经验,指出当时多数研究缺乏对照、仅PREVAIL II一项随机安慰剂对照试验且未获确定性结果。作者咨询美国国家过敏症和传染病研究所等专家,共识推荐下次暴发时以单克隆抗体鸡尾酒联合直接作用抗病毒药为组合策略开展随机对照临床试验。
要点
- 四种先导化合物来自单克隆抗体鸡尾酒和直接作用抗病毒药两类。
- 共识推荐下次埃博拉暴发采用单克隆抗体联合直接作用抗病毒的组合策略。
- 推荐以随机对照临床试验研究上述组合,尽管达到目标样本量可能困难。
核心结论
- 推荐下次埃博拉病毒病暴发时开展基于单克隆抗体与直接作用抗病毒药组合策略的随机对照临床试验,尽管达到目标样本量可能具有挑战性。
研究设计与样本
- 本文为J Infect Dis发表的建议类文章,咨询了来自制药业、美国国家过敏症和传染病研究所、其他美国政府机构及学术伙伴的临床与实验室专家,就抗埃博拉病毒病先导化合物的当前知识状况寻求共识。
主要发现
- 四种化合物来自2个不同类别(单克隆抗体鸡尾酒和直接作用抗病毒药)被列为先导候选。
- 2013—2016年西非埃博拉病毒病暴发期间仅开展了1项随机安慰剂对照临床试验(PREVAIL II),且因可供研究的新病例数减少而在获得确定性结果前终止。
- 大多数研究缺乏适当对照,研究方法各异,现场条件下完成研究面临巨大后勤挑战。
关键数值与推荐
- 共识推荐下次埃博拉病毒病暴发时以单克隆抗体联合直接作用抗病毒药的组合策略开展随机对照临床试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 大多数研究缺乏适当对照。
- 不同研究采用的研究方法各异。
- 现场条件下完成研究面临巨大后勤挑战。
- 仅1项随机安慰剂对照临床试验(PREVAIL II)因新病例数减少而在获得确定性结果前终止。
- 达到目标样本量可能具有挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2013-2016 outbreak of Ebola virus disease (EVD) in West Africa led to unprecedented morbidity and mortality. Although different classes of putative antiviral agents with supportive preclinical data were available for testing, and although several attempts to perform meaningful evaluation of these agents were undertaken during the epidemic, different research methods, a lack of appropriate controls in most studies, and formidable logistical challenges to completion of studies under field conditions hampered the success of these efforts. Ultimately only 1 randomized, placebo-controlled clinical trial (PREVAIL II) was performed in this setting, and, owing to a decrease in the number of new cases available for study, it, too, ended prior to reaching definitive results. Retrospective review of the lessons learned from this outbreak argues strongly for the need for much better preparedness in terms of selecting the trial design and drug(s) for use during the next outbreak. METHODS: Using recent data provided by representatives from the pharmaceutical industry, clinical and laboratory subject matter experts from the National Institute of Allergy and Infectious Diseases, other US government agencies, and academic partners were consulted regarding the current state of knowledge about several lead compounds with putative activity against EVD. Consensus was sought on recommendations concerning the most promising treatment strategies against EVD that should be studied in the context of a randomized clinical trial during the next outbreak. RESULTS: Four compounds from 2 different classes (monoclonal antibody [mAb] cocktails and direct-acting antiviral agents [DAAs]) were highlighted as lead candidates, limitations in the current knowledge base about these drug classes were reviewed, and recommendations about the optimal clinical research design for studying combinations of these different agents were made. CONCLUSIONS: Although achieving the desired sample size could be challenging, a randomized, controlled clinical trial based on a combination strategy of a mAb with a DAA was recommended as the most appropriate clinical trial design to be undertaken during the next outbreak of EVD.
引用
- Davey RT, Dodd L, Proschan M, et al. The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. J Infect Dis. 2018. PMID: 30032267. doi:10.1093/infdis/jiy334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。